Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with CD274 (PD-L1)-positive (CPS >/=1) recurrent or metastatic head and neck squamous cell carcinoma (PMID: 34844180; ESMO.org). | detail... 34844180 |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-048) that supported FDA approval, Keytruda (pembrolizumab) monotherapy significantly improved overall survival compared to Erbitux (cetuximab) plus chemotherapy (12.3 vs 10.3 months, HR=0.78, p=0.0086) in patients with CD274 (PD-L1)-positive (CPS >=1) metastatic or unresectable recurrent head and neck squamous cell carcinoma (PMID: 31679945; NCT02358031). | detail... 31679945 detail... |
| CD274 positive | head and neck squamous cell carcinoma | sensitive | Pembrolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (KEYNOTE-689) that supported FDA approval, neoadjuvant and adjuvant Keytruda (pembrolizumab) plus standard of case (SOC) significantly improved event-free survival compared to SOC (59.7 vs 29.6 months, HR=0.70, p=0.00140) and major pathological response rate difference (9.8%, p<0.00001) in patients with CD274 (PD-L1)-positive (CPS >=1) resectable locally advanced head and neck squamous cell carcinoma (PMID: 40532178; NCT03765918). | detail... 40532178 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| ESMO Clinical Practice Guidelines | Full reference... | |
| Full reference... | ||
| Full reference... | ||
| Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
| Keytruda (pembrolizumab) FDA Drug Label | Full reference... | |
| (31679945) | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. | Full reference... |
| (34844180) | Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. | Full reference... |
| (40532178) | Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. | Full reference... |